Biosimilar FSH Preparations Versus Highly Purified Urinary FSH for Simple Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome
2Department of Obstetrics and Gynecology, Al Azhar University, Egypt
3Department of Obstetrics and Gynecology, Assiut University, Egypt
Received Date: November 01, 2018; Published Date: November 13, 2018
Objective: To compare the efficacy of biosimilar FSH preparations and highly purified urinary FSH in ovulation induction in PCOs infertile women.
Patients and Methods: 100 infertile women with PCOs had been included in the study. Patients were randomly classified according to ovulation induction drugs used into 2 groups (Group I: included 50 infertile women received biosimilar FSH preparations and Group II: included 50 infertile women received highly purified urinary FSH. All cases were monitored for follicular development by transvaginal ultrasound.
Results: There was a mildly statistically significant difference between biosimilar FSH preparations group and highly purified urinary FSH in the mean ±SD of gonadotrophins doses used, the duration of stimulation, the number of mature follicles (p< 0.05), but there was a highly statistically significant in endometrial thickness at time of HCG triggering (p< 0.01). There was a mildly statistically significant difference in pregnancy rates (p< 0.05). There was a mildly statistically significant difference in development of hyperstimulation syndrome and twins’ pregnancies (p< 0.05).
Conclusion: Biosimilar FSH preparations were better than the highly purified urinary FSH in ovulation induction in PCOs infertile women (short duration and low doses of stimulation, significant increase in growing follicles number, enhancement in endometrial thickness and increased pregnancy rate). So, this study recommends the use of biosimilar preparations of FSH in ovulation induction in PCOs infertile women.
Keywords: Biosimilar FSH; Highly purified urinary FSH (HP-FSH); Polycystic ovary syndrome (PCOs)